Mose, Lucas

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2024 | 2023

2024

Ehret, Felix; Rueß, Daniel; Blanck, Oliver; Fichte, Susanne; Chatzikonstantinou, Georgios; Wolff, Robert; Mose, Lucas; Mose, Stephan; Fortmann, Thomas; Lehrke, Ralph; Turna, Menekse; Caglar, Hale Basak; Mortasawi, Farshin; Bleif, Martin; Krug, David; Ruge, Maximilian I; Fürweger, Christoph; Muacevic, Alexander (2024). Stereotactic radiosurgery and radiotherapy for brainstem metastases: An international multicenter analysis. International journal of cancer, 155(5), pp. 916-924. Wiley 10.1002/ijc.34980

Shelan, Mohamed; Achard, Vérane; Appiagyei, Felix; Mose, Lucas; Zilli, Thomas; Fankhauser, Christian D; Zamboglou, Constantinos; Mohamad, Osama; Aebersold, Daniel M; Cathomas, Richard (2024). Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate cancer and prostatic diseases, 27(3), pp. 422-431. Nature 10.1038/s41391-024-00829-9

Riggenbach, Elena; Mose, Lucas; Imboden, Sarah; Siegenthaler, Franziska Anna; Krause, Elke; Schlootz, Saskia; Rabaglio, Manuela Elena; Cihoric, Nikola; Lössl, Kristina; Wampfler, Julian (May 2024). Safety and efficacy of modern concurrent radiochemotherapy with Cisplatin and Gemcitabine. Radiotherapy and oncology, 194(1), S1119-S1120. Elsevier

Mose, Lucas; Aebersold, Daniel Matthias (May 2024). Prostate SBRT delivered with 1.5T MR-linac or Cyberknife: a propensity score matching analysis. Radiotherapy and oncology, 194(S1), S2543-S2544. Elsevier

Shelan, Mohamed; Mose, Lucas; Ahmadsei, Maiwand; Aebersold, Daniel Matthias (May 2024). Salvage Radiotherapy after Failure of Primary Focal Therapy for prostate cancer:A Systematic Review. Radiotherapy and oncology, 194(Supplement), S2614-S2615. Elsevier

2023

Schröder, Christina; Mose, Lucas; Mathier, Etienne; Zwahlen, Daniel Rudolf; Aebersold, Daniel Matthias; Förster, Robert; Shelan, Mohamed (2023). Five Fractions versus Seven Fractions SBRT for Intermediate- and High-Risk Prostate Cancer: A Propensity Score Matched Pair Analysis. Cancers, 15(24) MDPI AG 10.3390/cancers15245815

Schröder, Christina; Mose, Lucas; Förster, Robert; Mathier, Etienne; Zwahlen, Daniel R.; Aebersold, D. M.; Shelan, Mohamed (2023). Five fractions versus seven fractions SBRT for intermediate and high risk prostate cancer: a propensity score matched pair analysis. Strahlentherapie und Onkologie, 11(199), p. 1049. Springer

Provide Feedback